OS Therapies (OSTX)
Develops Listeria immunotherapy for recurrent metastatic osteosarcoma after surgery.
Something off on this page? Send us feedback.
Develops Listeria-based oncology immunotherapies and a preclinical drug-conjugate platform, with OST-HER2 targeting recurrent pulmonary metastatic osteosarcoma after surgery. Intended revenue depends on approvals, product sales, licensing and research collaborations, while operations rely on outside partners.
Develops oncology candidates centered on OST-HER2, an attenuated Listeria monocytogenes immunotherapy for recurrent pulmonary metastatic osteosarcoma after surgical resection. Other programs include OST-tADC, a preclinical silicon-linker drug-conjugate platform whose lead targets folate receptor alpha, plus acquired Listeria assets for non-small-cell lung cancer and prostate cancer.
Operates as a five-person, founder-led remote organization based in Maryland, using external clinical, regulatory, research and manufacturing partners across the United States, United Kingdom and India. Future revenue is intended to come from approved product sales, licensing and research collaborations, but it currently has no approved human product or drug-sale revenue.
Depends on follow-up data and regulatory decisions for OST-HER2, along with third-party manufacturing and recurring financing; it owns no manufacturing facilities or commercial sales organization.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $205.0K · Total debt $0 · Total assets $9.9M · Shareholders' equity −$10.8M
- Revenue
- $0
- Operating income
- −$8.6M
- Net income
- −$8.6M
No dividends on record.
| Institutions30 holders · as of Jun 30, 2026 | 6.28% | 2.90M shares | |
| Otherremainder | 93.72% | 43.23M shares |
46.13M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 1.69% | 777,651 | 13Fas of Jun 30, 2026 |
CM Management, LLCInstitution | 0.87% | 400,000 | 13Fas of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.65% | 301,794 | 13Fas of Jun 30, 2026 |
Howard Financial Services, Ltd.Institution | 0.54% | 248,001 | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 0.53% | 242,479 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Lantheus
Relapsed osteosarcoma program targeting overlapping patients.
- AstraZeneca (ADR)
Filing-named osteosarcoma rival with global oncology scale.
- AbbVie
Approved FRα ADC defining the ovarian-cancer benchmark.
- Genmab (ADR)
Late-stage FRα ADC in ovarian and endometrial cancer.
- Exelixis
Cabozantinib development reaches high-risk osteosarcoma.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OS Therapies | $1.75 | +2.04% | $77.9M | — | — | — | — |
| Lantheus | $100.50 | −0.33% | $6.56B | 24.4 | 18.3 | 4.2 | +2.7% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Genmab (ADR) | $34.33 | +0.34% | $21.01B | 27.0 | 26.6 | 2.1 | +24.9% |
| Exelixis | $59.11 | +0.96% | $14.71B | 18.3 | 15.8 | 6.0 | +10.6% |
| Median | 24.4 | 17.2 | 4.2 | +10.2% |